Description
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Location: CPMC (San Francisco)
Please contact: clinicalresearch@sutterhealth.org about study Viking NASH
View study details on ClinicalTrials.govPrincipal Investigator
Co-Investigator(s)
Kidist Yimam, MD, Todd Frederick, M.D., Raphael Merriman, MD
Recruitment Status
Active, Recruiting